National Health Service, Smoking cessation, Varenicline, Nicotine from

National Health Service Halts Varenicline Use in Smoking Cessation Due to Side Effects

Concerns over mental health risks lead to suspension of prescribing

The National Health Service (NHS) in the United Kingdom has suspended the use of the smoking cessation medication varenicline (Chantix) due to concerns over its potential side effects on mental health.

Mental health risks

Varenicline is a prescription drug that helps people quit smoking by reducing cravings and withdrawal symptoms. However, the NHS has received reports of patients experiencing serious mental health side effects, including: * Suicidal thoughts and behaviors * Hostility * Aggression * Anxiety * Depression * Insomnia * Seizures

These risks are particularly concerning in patients with a history of mental health conditions.

Suspension of prescribing

In light of these concerns, the NHS has decided to suspend the prescribing of varenicline with immediate effect. This decision was made after a review of the available evidence and consultation with experts in the field.

The NHS is now working to inform patients who are currently taking varenicline about the suspension and to provide them with alternative smoking cessation support.

Alternative smoking cessation options

There are a number of other effective smoking cessation treatments available, including: * Nicotine replacement therapy (NRT) * Bupropion (Wellbutrin) * Counseling * Behavioral therapy

Patients who are considering quitting smoking should speak to their doctor or a smoking cessation counselor to discuss the best option for them.

Conclusion

The NHS's decision to suspend the use of varenicline is a reminder of the importance of carefully considering the risks and benefits of all medications. Patients who are taking varenicline should be aware of the potential side effects and should speak to their doctor immediately if they experience any mental health problems.